283 related articles for article (PubMed ID: 29642934)
21. BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.
Coelho MA; Li S; Pane LS; Firth M; Ciotta G; Wrigley JD; Cuomo ME; Maresca M; Taylor BJM
BMC Biol; 2018 Dec; 16(1):150. PubMed ID: 30593278
[TBL] [Abstract][Full Text] [Related]
22. APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
Udquim KI; Zettelmeyer C; Banday AR; Lin SH; Prokunina-Olsson L
Carcinogenesis; 2020 Aug; 41(8):1030-1037. PubMed ID: 31930332
[TBL] [Abstract][Full Text] [Related]
23. A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
Siriwardena SU; Perera MLW; Senevirathne V; Stewart J; Bhagwat AS
Mol Cell Biol; 2019 Jan; 39(1):. PubMed ID: 30348839
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
[TBL] [Abstract][Full Text] [Related]
25. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
[TBL] [Abstract][Full Text] [Related]
26. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.
Taylor BJ; Nik-Zainal S; Wu YL; Stebbings LA; Raine K; Campbell PJ; Rada C; Stratton MR; Neuberger MS
Elife; 2013 Apr; 2():e00534. PubMed ID: 23599896
[TBL] [Abstract][Full Text] [Related]
27. An extended APOBEC3A mutation signature in cancer.
Langenbucher A; Bowen D; Sakhtemani R; Bournique E; Wise JF; Zou L; Bhagwat AS; Buisson R; Lawrence MS
Nat Commun; 2021 Mar; 12(1):1602. PubMed ID: 33707442
[TBL] [Abstract][Full Text] [Related]
28. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
29. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
Seplyarskiy VB; Soldatov RA; Popadin KY; Antonarakis SE; Bazykin GA; Nikolaev SI
Genome Res; 2016 Feb; 26(2):174-82. PubMed ID: 26755635
[TBL] [Abstract][Full Text] [Related]
30. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
[TBL] [Abstract][Full Text] [Related]
31. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase.
Serebrenik AA; Starrett GJ; Leenen S; Jarvis MC; Shaban NM; Salamango DJ; Nilsen H; Brown WL; Harris RS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22158-22163. PubMed ID: 31611371
[TBL] [Abstract][Full Text] [Related]
32. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms shaping the mutational landscape of the FRA3B/FHIT-deficient cancer genome.
Saldivar JC; Park D
Genes Chromosomes Cancer; 2019 May; 58(5):317-323. PubMed ID: 30242938
[TBL] [Abstract][Full Text] [Related]
34. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
35. Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B.
Adolph MB; Love RP; Feng Y; Chelico L
Nucleic Acids Res; 2017 Nov; 45(20):11925-11940. PubMed ID: 28981865
[TBL] [Abstract][Full Text] [Related]
36. Error-free versus mutagenic processing of genomic uracil--relevance to cancer.
Krokan HE; Sætrom P; Aas PA; Pettersen HS; Kavli B; Slupphaug G
DNA Repair (Amst); 2014 Jul; 19():38-47. PubMed ID: 24746924
[TBL] [Abstract][Full Text] [Related]
37. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
38. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
[TBL] [Abstract][Full Text] [Related]
39. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
[TBL] [Abstract][Full Text] [Related]
40. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
